Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.36 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196024 | 0.96 | — | — | |
| SCHEMBL3600351 | 0.76 | — | — | |
| SCHEMBL4917689 | 0.76 | GPR119 (0.42) | POLBLMNAGAAKMT2AMEN1 | |
| SCHEMBL958039 | 0.76 | — | — | |
| SCHEMBL786227 | 0.76 | — | — | |
| SCHEMBL29411916 | 0.76 | — | — | |
| SCHEMBL508369 | 0.76 | — | — | |
| SCHEMBL6487423 | 0.76 | — | — | |
| SCHEMBL3096827 | 0.76 | — | — | |
| SCHEMBL3083442 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659326-A | Defect-controllable porous material, preparation method thereof and alkane-alkene separation application | 浙江大学杭州国际科创中心 | 2024-03-08 | — | — | CN | disclosed |
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| EP-1368029-A4 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1368029-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | Farrington Pharmaceuticals, LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
| WO-2002062301-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | MEN1 2886/4885PDE4A 1984/4885POLB 2124/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | MEN1 2886/4885PDE4A 1984/4885POLB 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.